CYDY News and Press, CytoDyn Inc From 04/16/20

VANCOUVER, Washington, April 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...

CytoDyn (CYDY) continues to post impressive Leronlimab press releases that report hopeful accounts that the monoclonal antibody is able to have a positive impact on COVID-19 patient outcomes. It looks as if Leronlimab is able to mitigate the notorious "cytokine storm" that has been the culprit...

CytoDyn ( OTCQB:CYDY ) has treated the first patient in its Phase 2 basket trial for 22 solid cancer tumors. The patient has breast cancer, not triple-negative breast cancer. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...

VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, a...

April 14, 2020 Palm Beach, FL – April 14, 2020 – Many According to the World Health Organization (WHO) there are 70 coronavirus vaccines in development globally, with three candidates already being tested in human trials, as drugmakers race to find a cure for the dea...

More than 25 EINDs approved by FDA for leronlimab use in COVID-19 patients Phase 2 trial - As of last week, 12 patients enrolled from 2 sites; 3 more sites to initiate enrollment this week, for a total of 5 sites Phase 2b/3 trial - First hospital cleared to enroll patients beginning tod...

VANCOUVER, Washington, April 13, 2020 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the po...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

source: Investopedia I've recently been trading a lot of stocks associated with the COVID-19 pandemic, as well as gold stocks, as their volatility make for great opportunities to generate some serious profits quickly, based upon the rapid movement of the share price. While these moveme...